HTA Archives -

In March 2022, Leela Barham argued that, in light of new highs in the number of non-submissions to

Why companies don’t submit to NICE

https://pharmaphorum.com/market-access-2/why-companies-dont-submit-to-nice/

Patients/ Views & Analysis/ Views and analysis

UK-wide whole genome sequencing for newborns is feasible – but there are some key questions to answer first

mike.hammerton@pharmaphorum.com AstraZeneca, COVID-19, EFPIA, healthcare, HTA, NICE, sustainable healthcare 0 Comment

Genomics England, the Department of Health and Social Care’s genome-sequencing hub, has this year announced that support for

UK-wide whole genome sequencing for newborns is feasible – but there are some key questions to answer first

https://pharmaphorum.com/patients/public-approval-whole-genome-sequencing-newborn-screenings-uk-wide-rollout/

Patients/ Views & Analysis/ Views and analysis

What does the future of European healthcare look like?

Amanda Barrell AstraZeneca, COVID-19, EFPIA, healthcare, HTA, NICE, sustainable healthcare 0 Comment

After the “stress test” of COVID, how can the sector create resilient, sustainable healthcare systems for the long

What does the future of European healthcare look like?

https://pharmaphorum.com/patients/what-does-the-future-of-european-healthcare-look-like/

Patients/ Views & Analysis/ Views and analysis

How to balance the patient voice atop the shifting plates of HTA

Amanda Barrell ABPI, HTA, NICE 0 Comment

The tectonic plates of healthcare technology assessment (HTA) have shifted – but where does the patient voice fit

How to balance the patient voice atop the shifting plates of HTA

https://pharmaphorum.com/views-and-analysis/how-to-balance-the-patient-voice-atop-the-shifting-plates-of-hta/

Deep Dive/ Market Access/ Views & Analysis/ Views and analysis

Rethinking access barriers to innovation

mike.hammerton@pharmaphorum.com ATMP, Deep Dive, Deep Dive: Market Access, Executive Insight, HTA, market access 0 Comment

Market access issues don’t stop once a product has passed HTA – and this is especially true for

Rethinking access barriers to innovation

https://pharmaphorum.com/views-analysis-market-access/rethinking-access-barriers-to-innovation/

Market Access/ Podcast/ Video/ Views & Analysis/ Views and analysis

Galapagos UK’s Michael Smyth on RNA-based tech: the pharmaphorum podcast

mike.smith@pharmaphorum.com Galapagos, HTA, Michael Smyth, podcast, rna 0 Comment

Episode 35 of the pharmaphorum podcast hears from Michael Smyth about Galapagos UK and joining the company as

Galapagos UK’s Michael Smyth on RNA-based tech: the pharmaphorum podcast

https://pharmaphorum.com/market-access-2/podcast-galapagos-uk-michael-smyth-rna/

Deep Dive/ Market Access/ Views & Analysis/ Views and analysis

Deep Dive: Market Access

mike.hammerton@pharmaphorum.com Boehringer Ingelheim, Brexit, Deep Dive, digital health, HTA, market access, NICE, patient centricity, patient engagement, sales 0 Comment

It’s fair to say this is the most interesting time ever for market access. Not only has COVID

Deep Dive: Market Access

https://pharmaphorum.com/views-analysis-market-access/deep-dive-market-access-2021/

Market Access/ Views & Analysis/ Views and analysis

2021 market access prospects for France

Leela Barham EU market access, France, HTA 0 Comment

In the latest of a suite of features looking at the biggest markets in Europe, Leela Barham takes

2021 market access prospects for France

https://pharmaphorum.com/views-analysis-market-access/2021-market-access-prospects-for-france/

Digital/ News/ News

Okra says AI-based drug price predictor is 90% accurate

Phil Taylor artificial intelligence, digital, digital health, HEOR, HTA, Iqwig, machine learning, OKRA Technologies 0 Comment

UK artificial intelligence startup Okra Technologies has launched a new software platform that it claims can take the

Okra says AI-based drug price predictor is 90% accurate

https://pharmaphorum.com/news/okra-ai-based-drug-price-predictor-90-accurate/

Trending

HTA

Login